CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.

1:13-cv-01467

Overview

Case Number 1:13-cv-01467
Filing Date 2013-08-22
Status Terminated
Termination Date 2014-09-17
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Par Pharmaceutical Inc. Operating Company

Represented By

4 Attorneys Listed

Jennifer Koh

Email: jennifer.koh@lw.com

Gina R. Gencarelli

UNDELIVERABLE EMAIL 5/12/14

Katharine Lester Mowery

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7623

Richards, Layton & Finger, PA, One Rodney Square

Steven J. Fineman

Richards, Layton & Finger, PA

Tel: +1 (302) 658-6541

Richards, Layton & Finger, PA, One Rodney Square

Novartis AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

6 Attorneys Listed

Nicholas N. Kallas

Email: nkallas@venable.com

Filko Prugo

Email: filko.prugo@ropesgray.com

Dominick A. Conde

Email: dconde@venable.com

Daniel J. Minion

Email: dminion@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Plaintiff

Novartis Pharma AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Counter Defendant

LTS Lohmann Therapie-Systeme AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis International Pharmaceutical Ltd. Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 9 proceedings
🏛️
USPTO PTAB Trials 4 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): 🇩🇪 Germany GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (13 found):
PTAB: 4 U.S. Courts: 9
USPTO PTAB Trial 2014-11-13
IPR2015-00268

Mylan Pharmaceuticals Inc. et al. v. Novartis AG et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2014-11-13
IPR2015-00265

Mylan Pharmaceuticals Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (6316023)
Status: Final Written Decision
USPTO PTAB Trial 2014-04-02
IPR2014-00550

Noven Pharmaceuticals, Inc. et al. v. Novartis AG et al.

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2014-04-02
IPR2014-00549

Noven Pharmaceuticals, Inc. et al. v. Novartis AG et al.

U.S. Continuation Sibling (6316023)
Status: Final Written Decision
U.S. District Court 2015-11-05
1:15-cv-01025

Novartis Pharmaceuticals Corporation v. Amneal Pharmaceuticals LLC

Asserted Patent
Status: DED
U.S. District Court 2015-11-05
1:15-cv-01026

Novartis Pharmaceuticals Corporation v. Dr. Reddy's Laboratories, Ltd.

Asserted Patent
Status: DED
U.S. District Court 2014-06-19
1:14-cv-00777

Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-01-30
1:14-cv-00111

Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-04-03
1:13-cv-00527

Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-07
1:13-cv-00370

Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-03-07
1:13-cv-00371

Novartis Pharmaceuticals Corporation v. Actavis Inc.

Asserted Patent
Status: DED
U.S. District Court 2011-11-09
1:11-cv-01112

Novartis Pharmaceuticals Corporation v. Watson Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2011-11-03
1:11-cv-01077

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6335031
TTS containing an antioxidant
Filed: 1999-04-14
Issued: 2002-01-01
Expired (Term Ended)
Expires: 2019-04-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(42 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1354088.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG, Novartis Pharma AG, Novartis International Pharmaceutical Ltd., LTS Lohmann Therapie-Systeme AG. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(dmp, ) (Entered: 08/23/2013)

Entry #1 • 2013-08-22
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1354088.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG, Novartis Pharma AG, Novartis International Pharmaceutical Ltd., LTS Lohmann Therapie-Systeme AG. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(dmp, ) (Entered: 08/23/2013)

Entry #1 • 2013-08-22
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1354088.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG, Novartis Pharma AG, Novartis International Pharmaceutical Ltd., LTS Lohmann Therapie-Systeme AG. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(dmp, ) (Entered: 08/23/2013)

Entry #1 • 2013-08-22
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 08/23/2013)

Entry #2 • 2013-08-22
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/12/2013. Date of Expiration of Patent: 01/08/2019.Thirty Month Stay Deadline: 1/12/2016. (dmp, ) (Entered: 08/23/2013)

Entry #3 • 2013-08-22
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc